Protection of endogenous therapeutic peptides from peptidase activity through conjugation to blood components
View Patent ↗A method of synthesizing a modified therapeutic peptide capable of forming a peptidase-stabilized therapeutic peptide conjugate, the peptide having between 3 and 50 amino acids, is k. In a first step of the method, a therapeutic peptide having a carboxy terminal amino acid and amino terminal amino acid is synthesized. In a second step, pairs of cysteine residues present in the therapeutic peptide are sequentially and selectively oxidized to form disulfide bridges in the therapeutic peptide. In a third step, a protecting group is attached to remaining cysteine residues that do not form disulfide bridges in the therapeutic peptide. Finally, the peptide is coupled to a reactive group capable of reacting with amino groups, hydroxyl groups or thiol groups on a blood component to form a covalent bond therewith.
1. A method of synthesizing a modified therapeutic peptide capable of forming a peptidase-stabilized therapeutic peptide conjugate, the peptide comprising between 3 and 50 amino acids and having a carboxy terminal amino acid, an amino terminal amino acid, the method of comprising the steps of:
a) synthesizing the peptide from the carboxy terminal amino acid or the amino terminal amino acid,
b) sequentially and selectively oxidizing any pairs of cysteine residues in said therapeutic peptide to form disulfide bridges in said therapeutic peptide;
c) attaching a protecting group to any remaining cysteine residues that do not form said disulfide bridges in said therapeutic peptide; and
d) coupling a reactive group to the carboxy terminal amino acid, to the amino terminal amino acid, or to an amino acid between the carboxy terminal amino acid and the amino terminal amino acid, wherein the reactive group is capable of reacting with an amino group, an hydroxyl group or a thiol group on blood component to form a covalent bond therewith.
2. A method as claimed in claim 1 wherein the reactive group is selected from the group consisting of succinimidyl- and maleimido-containing groups.
3. A method as claimed in claim 2 wherein the reactive entity is a maleimido-containing group.
4. A method as claimed in claim 1 , further comprising bonding a lysine residue to said peptide, wherein the reactive group is coupled to the peptide via said lysine residue.
5. A method as claimed in claim 1 wherein the reactive group is coupled to the carboxy terminal amino acid of the peptide.
6. A method as claimed in claim 1 wherein the peptide does not contain a cysteine.
7. A method as claimed in claim 1 wherein the therapeutic peptide contains two cysteines, the two cysteines are oxidized to form a disulfide bridge, and the reactive group is coupled to the peptide.
8. A method as claimed in claim 6 wherein the peptide is synthesized from the carboxy terminal amino acid.
9. A method of synthesizing a modified therapeutic peptide and forming a peptidase-stabilized therapeutic peptide conjugate, the peptide comprising between 3 and 50 amino acids and having a carboxy terminal amino acid and an amino terminal amino acid, the method comprising the steps of
synthesizing the peptide from the carboxy terminal amino acid,
coupling a maleimido-containing group, to the carboxy terminal amino acid, the amino terminal amino acid, an amino acid between the carboxy terminal amino acid and the amino terminal amino acid, and
reacting the maleimido-containing group with a thiol group on a blood component to form a covalent bond therewith.
10. A method as claimed in claim 9 wherein the maleimido-containing group is coupled to the carboxy terminal amino acid.
11. A method as claimed in claim 9 , further comprising bonding a lysine residue to said peptide, wherein the maleimido-containing group is coupled to the peptide via said lysine residue.
12. A method as claimed in claim 9 wherein said reacting step occurs in vivo.
13. A method as claimed in claim 9 wherein said reacting step occurs ex vivo.